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Abstract
Stimulation of CD40 or Toll-Like Receptors (TLR) has potential for tumor immunotherapy. Combinations of CD40 and TLR
stimulation can be synergistic, resulting in even stronger dendritic cell (DC) and CD8+ T cell responses. To evaluate such
combinations, established B16F10 melanoma tumors were injected every other day X 5 with plasmid DNA encoding a
multimeric, soluble form of CD40L (pSP-D-CD40L) either alone or combined with an agonist for TLR1/2 (Pam3CSK4 ), TLR2/6
(FSL-1 and MALP2), TLR3 (polyinosinic-polycytidylic acid, poly(I:C)), TLR4 ( monophosphoryl lipid A, MPL), TLR7 (imiquimod),
or TLR9 (Class B CpG phosphorothioate oligodeoxynucleotide, CpG). When used by itself, pSP-D-CD40L slowed tumor
growth and prolonged survival, but did not lead to cure. Of the TLR agonists, CpG and poly(I:C) also slowed tumor growth,
and the combination of these two TLR agonists was more effective than either agent alone. The triple combination of
intratumoral pSP-D-CD40L + CpG + poly(I:C) markedly slowed tumor growth and prolonged survival. This treatment was
associated with a reduction in intratumoral CD11c+ dendritic cells and an influx of CD8+ T cells. Since intratumoral injection
of plasmid DNA does not lead to efficient transgene expression, pSP-D-CD40L was also tested with cationic polymers that
form DNA-containing nanoparticles which lead to enhanced intratumoral gene expression. Intratumoral injections of pSP-D-
CD40L-containing nanoparticles formed from polyethylenimine (PEI) or C32 (a novel biodegradable poly(B-amino esters)
polymer) in combination with CpG + poly(I:C) had dramatic antitumor effects and frequently cured mice of B16F10 tumors.
These data confirm and extend previous reports that CD40 and TLR agonists are synergistic and demonstrate that this
combination of immunostimulants can significantly suppress tumor growth in mice. In addition, the enhanced effectiveness
of nanoparticle formulations of DNA encoding immunostimulatory molecules such as multimeric, soluble CD40L supports
the further study of this technology for tumor immunotherapy.
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Introduction
A number of immunostimulants, such as anti-CTLA4 antibody
[1], have been shown to be efficacious in treating established
tumors in mice and several of these agents have advanced to
clinical trials in humans. Recently, it has been shown that the local
application of Toll-Like Receptor (TLR) agonists may have
antitumor effects [2,3,4,5]. For example, imiquimod cream
(Aldera
TM) is effective for lentigo maligna (an in situ form of
melanoma) [6] and basal cell carcinoma [7]. Equally promising in
mice but difficult to apply in humans is the use of CD40
stimulation. Numerous studies have shown that agonistic antibody
to CD40 can have major antitumor effects either on its own
[8,9,10,11,12] or when combined with TLR agonists
[13,14,15,16]. However, agonistic anti-CD40 antibody can be
toxic, especially if used repeatedly [12,17]. CD40L itself has been
used in several circumstances. As a single-trimer, soluble protein
(sCD40LT, Avrend
TM, Immunex/Amgen), systemic therapy had
significant antitumor effects, but also produced dose-limiting
hepatic toxicity [18]. Efforts to deliver CD40L by injecting
adenoviral vectors directly into tumors have shown promise
[19,20]. Alternatively, the co-delivery of CD40L along with
defined tumor antigens may produce strong antitumor effects
[21,22].
From an immunological point of view, most of these
immunostimulants activate dendritic cells from a resting, tolero-
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doing, these immunostimulants counteract the deactivating effects
of tumors on the dendritic cells in their immediate environment
[23,24,25]. A recent insight is that DC activation is not a simple
on/off switch but rather is a tunable pathway leading to
qualitatively and quantitatively different outputs. For IL-12p70
production by DCs, for example, Napolitani et al. [26] found that
the combination of two TLR agonists (e.g., poly(I:C) for TLR3
and R-848 for TLR7/8) was markedly synergistic, and the
addition of CD40L led to a further 10- to 100-fold increase in IL-
12p70 production. Zheng et al. showed the antitumor effects of
CpG plus poly(I:C) stimulation of DC-tumor cell electrofusion
hydrids [27]. Wells et al. have shown the antitumor effects of a
combination of agonistic anti-CD40 antibody, CpG, poly(I:C),
and IFN-c delivered as a emulsion in squalene and Tween 80 [28].
These finding support earlier reports that CD40 stimulation
combined with TLR agonists is capable of inducing strong
antitumor CD8+ T cell responses [13,14].
The present study was undertaken to examine the effects of
combinations of TLR agonists along with a new form of CD40L
that dramatically enhanced CD8+ T cell responses in a murine
DNA vaccine model [29]. This form of CD40L was produced by
fusing the extracellular domain of CD40L with the body of
surfactant protein D (a spontaneously multimerizing molecule)
resulting in a 4-trimer soluble protein encoded by the plasmid
pSP-D-CD40L. In these previous studies, SP-D-CD40L led to
enhanced CD40 activation and increased immune activation both
in vitro and in murine vaccine models [29,30]. In the present
study, we used the B16F10 melanoma because it is a frequently
studied, poorly immunogenic, spontaneously metastasizing tumor
model that is very difficult to treat using immunotherapy [31].
Significantly, pSP-D-CD40L, CpG, and poly(I:C) showed activity
when injected directly into established tumors every other day X 5.
Synergy between these two TLR agonists and synergy between
pSP-D-CD40L and TLR agonists were observed. In addition,
enhanced delivery of pSP-D-CD40L in nanoparticles formed with
cationic polymers increased the antitumor effects, indicating that
DNA delivery into tumors is a surmountable barrier to this type of
immunotherapy. Taken together, these studies show that DNA
delivery of multimeric soluble CD40L is a practical means for
providing CD40 stimulation in vivo.
Materials and Methods
Tumor Immunotherapy Plasmids
The construction of the CD40L and GITRL plasmids was
previously described [29,32]. The following murine plasmids were
tested: pTr-CD40L, encoding 1-trimer soluble CD40L; pAcrp30-
CD40L, encoding a 2-trimer soluble form of murine CD40L; pSP-
D-CD40L, encoding a 4-trimer soluble form of murine CD40L;
pSP-D-GITRL, encoding a 4-trimer soluble form of murine
GITRL; and pcDNA3.1(+) (Invitrogen, Carlsbad, CA) empty
vector as a control.
Plasmid preparation
Plasmids were propagated in E. coli strains XL1 blue or TOP10.
Supercoiled plasmid DNA was isolated by anion-exchange
chromatography resin (EndoFree Plasmid MaxiKit, QIAgen,
Inc, Valencia, CA). Initial experiments indicated that the empty
control vector pcDNA3.1 isolated by this method was capable of
inducing an antitumor effect in mice, despite the fact that it was
negative for endotoxin (,0.1 EU/ml) by Limulus Assay (QCL-
1000, BioWhittaker, Walkersville, MD). Consequently, an addi-
tional purification step using Triton X-114 detergent extraction
was used for the experiments shown in Figs. 1, 3–6 [33].
To prepare Triton X-114 detergent (Sigma, St. Louis, MO), it
was pre-equilibrated by adding 10 volumes TE buffer (10 mM
TRIS-HCl, 0.1 mM EDTA, pH 8.0), vortexed, incubated at 4uC
for 6 hours, and then held at 37uC overnight. The later
temperature is above the cloud point of Triton X-114, which
then separates into a sublayer. At this point, the upper aqueous
phase and any turbid material at the interface were removed and
the detergent sublayer was harvested. This procedure was
repeated a total of three times. The resulting buffer-equilibrated
Triton X-114 was then stored below its cloud point at 4uC.
To use Triton X-114 after completing the EndoFree kit
purification protocol above, plasmid DNA was suspended in
endotoxin-free TE buffer (pH 8.0) at a concentration of 0.8 mg/
ml. Endotoxin-free 3M sodium acetate, pH 5.2 (Sigma) was added
to a final concentration of 0.3 M. Then a total of 0.03 volumes of
pre-equilibrated Triton X-114 were added to the DNA solution
(e.g., 30 ml per 1 ml) and the sample was vortexed thoroughly.
After incubation below the Triton X-114 cloud point on ice for 15
minutes, the sample was heated to 37uC for 10 minutes to allow
the two phases to separate, followed by centrifugation at 400 x g
for 2 minutes at room temperature. The upper aqueous phase
containing the DNA was then transferred to a new tube and
another two cycles of extraction were performed for a total of three
detergent extractions. Plasmid DNA in the final upper aqueous
phase was precipitated by the addition of 0.7 volumes of room
temperature isopropanol, followed by centrifugation at
13,000 rpm in a microcentrifuge for 10 minutes. The DNA pellet
was then washed with cold 70% ethanol (endotoxin free), air-dried
briefly, and dissolved in endotoxin-free TE buffer (pH 8.0) at 4uC
for 1–2 days. The final plasmid concentrations were typically 5–
7 mg/ml. The control pcDNA3.1 plasmid prepared in this
manner had minimal antitumor effects, confirming the removal
of an immunostimulatory contaminant in the initial plasmid DNA
prepared using the EndoFree kit. Prior to injection into mice,
plasmid DNA was diluted in Dulbecco’s calcium- and magnesium-
free phosphate buffered saline (PBS) to a concentration of 1 mg/
ml (50 mg per 50 ml injection).
EndoFree DNA without Triton X-114 processing was used in
the experiment in Fig. 2. As shown, pcDNA3.1 plasmid prepared
in this manner slowed tumor growth but did not significantly
prolong survival. Nevertheless, to avoid this potentially confound-
ing effect, all other experiments were performed using EndoFree
DNA processed by the Triton X-114 extraction protocol above.
Also, whenever plasmid DNA was loaded into 0.5 ml insulin
syringes, the 28G needle was first removed with pliers before
drawing up the DNA in order to avoid shearing the supercoiled
plasmids, following which the needle was reattached for injection
into mice.
Polymer DNA nanoparticles
Polyethylenimine (PEI) nanoparticles were made using In Vivo
JetPEI
TM and 10% glucose solution (Q-Biogene Inc., Montreal,
Canada). First, the 10% glucose solution was diluted to 5% glucose
using endotoxin-free sterile water for injection (Baxter, Deerfield,
IL). Then the plasmid DNA stock in TE buffer (5–8 mg/ml) was
diluted with 5% glucose solution to a final concentration of 1 mg
DNA/ml volume. Separately, one part In Vivo JetPEI
TM stock was
diluted in 9 parts 5% glucose solution and mixed. Then, for each
mouse injected, 50 ml of DNA solution was mixed with 50 mlo fI n
Vivo JetPEI
TM solution, pulse vortexed, quick spun in a
microcentrifuge, and then allowed incubate at room for at least
for 15 minutes prior to use. Tumors were injected with 100 mlo f
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concentration of 0.5 mg/ml in isotonic 5% glucose. This corre-
sponds to an N/P ratio of 10:1, i.e., 10 nitrogen residues of PEI
per DNA phosphate.
Solid C32 polymer was synthesized at MIT and shipped on dry
ice to San Diego. It was dissolved at 100 mg/ml in cell-culture
grade sterile DMSO (Sigma-Aldrich, St. Louis, MO) at room
temperature for 2 hours, following which the hygroscopic solution
was aliquoted and stored at 280uC until use. C32 plasmid DNA
nanoparticles were prepared shortly before use. The following
steps yielded 500 ml of nanoparticle solution which is sufficient to
inject 100 ml/tumor in 5 mice, and the actual amounts were scaled
up proportionally according to the number of mice used. First,
using a 1.5 ml microcentrifuge tube, plasmid DNA was added to
sterile water for injection to make a final DNA concentration of
5 mg/ml in a volume of 50 ml. In a separate microcentrifuge tube,
sterile water was used to prepare 25 mM sodium acetate from a
commercial solution of 3 M sodium acetate, pH 5.2 (Sigma-
Aldrich). Then 75 ml of the 25 mM sodium acetate solution was
added to the tube containing 50 ml of DNA. Because the DNA was
diluted from a stock dissolved in TE pH 8.0 (as opposed to DNA
prepared in water as originally described by Anderson et al. [34]),
there was a concern that the TRIS buffer could raise the pH in
subsequent steps. Consequently, an additional 3 ml of 3 M sodium
acetate, pH 5.2 was added to this 125 ml DNA-containing
mixture. Then the tube was pulse vortexed to mix and quick
spun to position the solution at the bottom of the tube. Second, in
a separate microtube, the C32 solution was prepared at room
temperature by combining 75 ml of cell-culture grade DMSO and
50 ml of the C32 stock solution (100 mg/ml in DMSO), pulse
vortexed to mix, and then quick spun. Next, 125 ml of this C32
solution was added to the tube containing 125 ml of the DNA/
sodium acetate solution, gently mixed by hand, and then quick
spun. The resulting 250 ml solution was allowed to incubate at
room temperature for 5 minutes. Lastly, 280 ml of calcium- and
magnesium-free PBS was added to the 250 ml of C32 DNA mix,
pulse vortexed, quick spun, and then 500 ml was loaded into a
syringe for the injections (the extra 30 ml of PBS volume assured
that a full 500 ml could be loaded into the syringe).
TLR Agonists
TLR agonist compounds were prepared following their
manufacturer’s instructions. TLR1/2 agonist Pam3CSK4 (Invivo-
Gen, San Diego, CA) was suspended at 1 mg/ml in PBS and
administered at 5 mg per injection. TLR2/6 agonist FSL-1
(InvivoGen) was suspended at 0.2 mg/ml in PBS and adminis-
tered at 1 mg per injection. The synthetic mycoplasmal lipoprotein
and TLR2/6 ligand MALP2 (InvivoGen) was suspended in PBS at
a concentration of 0.2 mg/ml and administered at 3 mg per
injection. TLR3 agonist poly(I:C) (GE Amersham, Piscataway, NJ)
was prepared by adding 20 ml PBS to the 50 mg in the vial,
incubating at 60uC for 20 minutes, and then placing the vial in a
beaker containing 100 ml water at room temperature to allow the
RNA strands to slowly hybridize. Following this, the 2.5 mg/ml
solution was aliquoted and stored at 280uC. Just prior to use, the
poly(I:C) stock was diluted 1:5 in PBS to provide a 500 mg/ml
Figure 1. Antitumor effects of plasmids for multimeric, soluble CD40L and GITRL on established B16F10 melanoma tumors. B16F10
cells were injected s.c. in C57BL/6 mice. When the tumors were $4 mm in diameter, they were injected every other day X 5 with 50 mg of plasmid
DNA. Three forms of CD40L were tested as fusion proteins (see text): 1-trimer soluble CD40L (pTr-CD40L); 2-trimer CD40L (pAcrp30-CD40L); and 4-
trimer CD40L (pSP-D-CD40L). Additionally, a 4-trimer form of GITRL (pSP-D-GITRL) was tested for comparison. The negative control injections were
either PBS or the empty expression plasmid pcDNA3.1. Panel A – Treatment with pSP-D-CD40L or pSP-D-GITRL slowed the growth of
established B16F10 tumors. Each graph shows 5 mice per group for each treatment where day 0 indicates the time when the tumor became
$4 mm and injections began and ending when fewer than 3 mice in each group remain alive. Injections continued every other day X 5, ending on
day 8 (arrows). There was a significant reduction in tumor size (mean6SEM, n=5) compared to control pcDNA3.1 or PBS using 2-trimer pAcrp30-
CD40L, 4-trimer pSP-D-CD40L, and 4-trimer pSP-D-GITRL on day 8 as measured before the final injection (p,0.05 by Student’s t test). Panel B –
Treatment of established B16F10 tumors with pSP-D-CD40L significantly prolonged survival. While treatment with plasmids for all 3
forms of CD40L and 4-trimer GITRL showed a trend toward enhanced survival, this was only statistically significant for the 4-trimer pSP-D-CD40L
plasmid (p,0.01 by log-rank test). Consequently pSP-D-CD40L was selected for further study.
doi:10.1371/journal.pone.0007334.g001
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TLR4 agonist monophosphoryl lipid A (MPL), a detoxified form
of lipid A (Avanti Polar Lipids, Alabaster, AL), was dissolved in
50% ethanol at 1 mg/ml and administered at 10 mg per injection.
TLR7 agonist imiquimod acetate (Sequoia Research Products,
Oxford, UK) was suspended in particulate form in a mixture of
1.5% Methylcellulose and 0.5% Tween 80 [35] at a concentration
of 10 mg/ml and administered at 25 mg per injection. TLR9
agonist CpG 1018 59-TGACTGTGAACGTTCGAGATGA-39
(all DNA linkages phosphorothioate), a B Class CpG, was a gift of
Dr. Eyal Raz [36] or was purchased from Trilink Biotechnologies
(San Diego, CA) as a reverse phase-HPLC purified product. The
lyophilized CpG 1018 powder was resuspended in water at a
concentration of 5 mg/ml and stored at 280uC until use. Just
prior to use, the CpG stock was diluted 1:5 in PBS to provide a
500 mg/ml working solution of which 25 mg was administered per
Figure 2. A screen of TLR agonists showed that CpG and poly(I:C) had additional antitumor effects when combined with 4-trimer
CD40L plasmid DNA. Panels A and B – The combination of 4-trimer pSP-D-CD40L with CpG or poly(I:C), but not other TLR agonists
tested, slowed the growth of established B16F10 tumors. As before, tumors that were $4 mm in diameter were injected with pSP-D-CD40L
in combination with selected TLR agonists every other day X 5 (arrows). There were no apparent additive effects of Pam3CSK4 (TLR1/2), Malp2 (TLR2/
6), FSL1 (TLR2/6), MPL (TLR4), and imiquimod (TLR7) (Panel A, mean6SEM, n=5). The addition of poly(I:C) (TLR3) to pSP-D-CD40L showed a
significantly stronger effect on tumor growth than pSP-D-CD40L alone from day 14 (Panel B, p,0.05 by Student’s t test). CpG was clearly active when
added to pSP-D-CD40L as compared to pSP-D-CD40L alone from day 14 (Panel B, p,0.01 by Student’s t test). Panels C and D – The addition of
CpG to pSP-D-CD40L resulted in a further survival benefit for mice with established B16F10 tumors. As expected from the tumor
growth data, there was no increase in survival when Pam3CSK4, Malp2, FSL1, MPL, or imiquimod were added to pSP-D-CD40L treatment (Panel C).
While the addition of poly(I:C) to pSP-D-CD40L showed a trend toward improved survival, this was not statistically significant when compared to pSP-
D-CD40L alone (Panel D). In contrast, the addition of CpG to pSP-D-CD40L showed a clear survival benefit when compared to pSP-D-CD40L alone
(Panel D, p,0.01 by log-rank test).
doi:10.1371/journal.pone.0007334.g002
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endotoxin-free. The volume of the TLR agonist injections was
held constant at 50 ml, using PBS as necessary to adjust the total
amount to this volume.
Tumor Cell Lines
B16F10 melanoma from C57BL/6 mice [37] was obtained
from the American Type Culture Collection (ATCC), Manassas,
MD. Cells were cultured in RPMI 1640, 2 mM L-glutamine, and
10% FBS (HyClone, Thermo Fisher Scientific, Waltham, MA),
and were negative for mycoplasma and other adventitious agents
by PCR testing (IMPACT II, RADIL, University of Missouri).
Tumor Initiation and Immunotherapy
Mice were studied under a protocol approved by the
Institutional Animal Care and Use Committee of the VA San
Diego Healthcare System, and the ‘‘rinciples of laboratory
animal care’’(NIH publication No. 85–23, revised 1985) were
followed. Cultured tumor cells were detached from flasks using
trypsin/EDTA followed by neutralization with cold RPMI +10%
FBS and pelleting at 300 x g for 6 minutes. The cells were then
washed 3 times with cold PBS and resuspended at 5610
6 cells/
ml in PBS. To initiate tumors, a total of 5610
5 cells (0.1 ml) were
injected subcutaneously intotheabdomen of 6–8week old female
C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME).
When the s.c. tumors became palpable and measured $4m mi n
diameter (determined as the mean of two orthogonal measure-
ments), the mice were eartagged and considered to be at day 0 of
the treatment protocol. Prior to performing the injections into
tumors, mice were first lightly anesthetized with isoflurane gas.
Then a total of 100 ml of DNA solution or 50 ml of TLR agonists
were injected into or around the tumor using a 0.5 ml insulin
s y r i n g ew i t ha2 8g a u g en e e d l e .When combinations of plasmid
DNA and TLR agonists were used, the DNA was injected on
days 0, 2, 4, 6, and 8, and the TLR agonists were injected the
n e x td a yo nd a y s1 ,3 ,5 ,7 ,a n d9 .T h i ss c h e d u l ew a sb a s e do na
report that dendritic cells are best stimulated when TLR
stimulation follows CD40 stimula t i o nr a t h e rt h a nt h er e v e r s eo r
simultaneously [38]. For all treatments, peritumoral injections
were repeated every other day for a total of 5 plasmid DNA
injections. The tumor diameter in two orthogonal dimensions
was measured with an electronic caliper beginning on the day of
initial injection and every other day until the endpoint was
reached. Mice were euthanized when tumors became $15 mm
in mean diameter or ulcerated. Survival was calculated as the
number of days from the first inj e c t i o no nd a y0w h e nt h et u m o r s
were $4 mm in diameter until the mice were either found dead
or required euthanasia.
Tumor Histology
Tumor cells were injected s.c. (5610
5 per mouse) on the
abdomen and allowed to grow to at least 7 mm in diameter. Mice
were then given peritumoral injections of immunostimulatory
compounds every other day X 5 (as detailed above) and then
euthanized two days later on day 10 by pentobarbital injection.
The tumors were excised and divided so that one half was fixed in
1% paraformaldehyde and embedded in paraffin, and the other
half was flash frozen in OCT compound (Tissue-Tek, Thermo
Fisher Scientific). Serial sections (10 mm in thickness) were
obtained from the paraffin-embedded tissue and processed for
hematoxylin and eosin staining. For immunofluoresence micros-
copy, the OCT-embedded tissue was cut into 10 mm serial sections
with a cryostat and stained by standard antibody methods. The
following antibodies were used: fluorescein-conjugated CD11c
clone HL3 (BD Pharmingen, San Diego, CA); phycoerythrin (PE)-
conjugated CD8 clone 53–6.7 (BD Pharmingen); and biotinylated
F4/80 clone BM8 (eBioscience, San Diego, CA) which was used
with PE-conjugated streptavidin (BD Pharmingen). Slides were
examined with a Zeiss Axioskop microscope and images were
recorded using an Optronics CCD camera. Duplicate tumors were
evaluated for each condition.
Statistics
In order to compare tumor growth, the geometric mean tumor
diameters of surviving mice were compared on the days stated
using Student’s t test (Prism 4.0 Software, GraphPad Systems, San
Diego, CA). To compare Kaplan-Meier survival plots, a log-rank
test (Mantel-Haenszel method) was used to determine the
significance of the differences in survival between groups. A p
value of ,0.05 was considered significant.
Results
Characteristics of the B16F10 melanoma model in C57BL/
6 mice
We deliberately chose B16F10 melanoma as a treatment-
resistant tumor model that could be used to discriminate between
strongimmunotherapy regimens.B16F10 is ideal for this purpose
because it is (1) poorly immunogenic, (2) lacks foreign antigens,
(3) fast growing, (4) highly metastatic, and (5) rapidly fatal. (1)
B16F10 is poorly immunogenic. Of all of the B16 sublines tested,
B16F10 has the lowest level of surface MHC Class I and almost
unmeasurable amounts of antigen processing machinery com-
p o n e n t s( T A P 1 ,L M P 2 ,L M P 7 ,L M P 1 0 ,P A 2 8 a,a n dP A 2 8 b),
although these proteins could be significantly upregulated by
treatment with interferon-c [39]. (2) B16F10 lacks foreign
antigens that are likely to be recognized by the immune system.
Instead, its principal rejection antigen is tyrosinase-related
protein 2 (TRP2), a self-antigen that tends to elicit low affinity,
poorly functional CD8+ T cell responses [40]. In contrast, some
studies use B16F10 transfected with chicken ovalbumin, a foreign
antigen that is sometimes maintained in cells using the neo gene
for G418 selection which is itself a strong antigen for immune
rejection [41]. Even green fluorescent protein (GFP) is a foreign
antigen in mice [42]. The presence of such foreign antigens can
artifactually increase the antigenicity of otherwise poorly
immunogenic tumor cells and thereby confound the results of
an immunotherapy study. (3) B16F10 is fast growing compared
with many tumors commonly studied. As a result, B16F10 is
harder to treat than tumors formed from either parental B16 cells
or more slowly growing variants of this tumor cell line such as
B16-BL6. For example, B16-BL6 was used in the original
description of therapeutic vaccination with irradiated GM-CSF-
transfected tumor cells and blocking antibody to CTLA-4. In that
study, 10
4 B16-BL6 tumor cells were injected to initiate a tumor
and the treatment had to be given by day 4 postinjection at which
time the tumors were barely measurable [43]. In the present
study, in contrast, tumors were initiated by injecting 50X more
cells (5610
5 rapidly growing B16F10 cells) and treatment was
delayed for 5–7 days until the tumors were $4m mi nm e a n
diameter. (4) B16F10 is highly metastatic by design. Fidler
originally derived the B16F10 subline by injecting parental B16
cells intravenously, harvesting tumor cells from a lung metastasis,
and then repeating this procedure for a total of 10 cycles [44]. (5)
B16F10 is rapidly fatal, generally within 10 days of s.c. injection
under the conditions employed here. To be effective, this means
that an antitumor immunotherapy must induce strong immunity
very quickly in order to overtake the tumor’s rapid growth.
CD40L Nanoparticles and TLRs
PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7334For established B16F10 melanoma, local treatment with
plasmid DNA for multimeric soluble CD40L, pSP-D-
CD40L, slowed tumor growth and prolonged survival
Previous studies have shown that CD40L is most effective when
it clusters its receptor, CD40, on the membranes of responding
cells [45,46]. In our previous study [29], we used the pcDNA3.1
expression vector to prepare plasmids encoding soluble CD40L
with varying degrees of valency by fusing the extracellular domain
(ECD) of CD40L with multimerization scaffolds selected from
other proteins. A plasmid for 1-trimer soluble CD40L, pTr-
CD40L, was produced by fusing an N-terminal isoleucine zipper
to the CD40L ECD, similar to the widely studied sCD40LT
(Avrend
TM Immunex/Amgen) [47]. A plasmid for 2-trimer
CD40L, pAcrp30-CD40L, was produced by fusing the body of
Acrp30 (a V-shaped molecule with two trimeric arms) with the
CD40L ECD [48]. A plasmid for 4-trimer CD40L, pSP-D-
CD40L, was produced by fusing the body of surfactant protein D
(an X-shaped molecule with four trimeric arms) with the CD40L
ECD. In the previous DNA vaccine study [29], the adjuvant
activity of soluble CD40L was directly proportional to the number
of trimers per molecule (4.2.1), with pSP-D-CD40L being most
active.
To determine if soluble CD40L multivalency was also
important in the tumor immunotherapy setting, established
B16F10 tumors were injected peritumorally with PBS alone,
control empty expression plasmid pcDNA3.1, or plasmids for the
three soluble forms of CD40L: 1-trimer pTr-CD40L; 2-trimer
pAcrp30-CD40L; and 4-trimer pSP-D-CD40L. An alternative
TNF superfamily (TNFSF) molecule, GITRL, was also tested as a
4-trimer soluble protein construct (pSP-D-GITRL) [29].
As shown in Fig. 1A, tumor growth was significantly slowed
after peritumoral injections of plasmids for 4-trimer CD40L (pSP-
D-CD40L) as compared to empty vector (beginning on day 8
tumor size measurements differed at the p,0.05 level by Student’s
t test). If PBS was used for comparison, then 2-trimer CD40L
(pAcrp30-CD40L) and 4-trimer GITRL (pSP-D-GITRL) also
appeared to slow tumor growth from day 8 (p,0.05). However,
PBS is an unsatisfactory control because DNA itself may have mild
immunostimulatory effects [49,50]. As shown in Fig. 1B, there was
a trend toward prolonged survival with all of the TNFSF
molecules, but statistical significance with this small number of
animals (n=5/group) was only reached using 4-trimer pSP-D-
CD40L (p,0.01, log-rank test compared with PBS or pcDNA3.1).
For this reason, the 4-trimer version of soluble CD40L (pSP-D-
CD40L) was selected for further studies.
For established B16F10 melanoma, pSP-D-CD40L
combined with either CpG or poly(I:C) resulted in
stronger antitumor effects than pSP-D-CD40L alone
Both in vitro [26,51,52,53] and in vivo studies [13,14,54,55]
have noted a more than additive effect of combining agonistic anti-
CD40 antibody with TLR agonists such as CpG oligonucleotide,
poly(I:C) and derivatives of the TLR7 agonist imiquimod.
However, due to the potential toxicity of agonistic anti-CD40
antibody treatment [17], the application of agonistic anti-CD40
antibodies to humans may be problematic [8]. In contrast, we
observed no toxic effects when pSP-D-CD40L was used as an
adjuvant in the prior DNA vaccine study [29]. Consequently,
synergistic interactions between pSP-D-CD40L and TLR agonists
were sought. Established B16F10 tumors were treated with a
combination of pSP-D-CD40L (50 mg injected peritumorally
every other day X 5) with or without selected TLR agonist
compounds, prepared and dosed as described in Methods. As
shown in Figs. 2A and 2B, most of the TLR agonists tested failed
to improve upon the antitumor effects of pSP-D-CD40L alone.
We cannot rule out that many of these TLR agonists would have
been more effective if they had been formulated or administered
differently. In contrast, the combination of pSP-D-CD40L + CpG
or pSP-D-CD40L + poly(I:C) significantly inhibited tumor growth
(Fig. 2C, p,0.01 and p,0.05 respectively from day 14 by
Student’s t test). The finding that poly(I:C) synergized with pSP-D-
CD40L is similar to the report of Liu et al. that poly(I:C) combined
with agonistic CD40 antibody protected mice from J558
plasmacytoma tumors [14]. There was a trend toward a further
survival advantage when CpG or poly(I:C) was added to pSP-D-
CD40L, but this difference was only statistically significant with
CpG using this small number of animals (Fig. 2D, p,0.01 by log-
rank test comparing pSP-D-CD40L with pSP-D-CD40L + CpG,
n=5/group).
For established B16F10 melanoma, pSP-D-CD40L
combined with two active TLR agonists resulted in
increased antitumor activity
Napolitani et al. reported that the triple combination of cells
bearing membrane CD40L plus two different TLR agonists (LPS
+ poly(I:C), LPS + R848, or poly(I:C) + R848) could produce even
stronger DC stimulation than that seen with CD40L and a single
TLR agonist [26]. It was suggested that the combination of a
MyD88 pathway agonist with a TRIF pathway agonist was
important for the TLR synergy observed [26,56]. To test this
possibility in the B16F10 tumor system, various combinations of
pSP-D-CD40L, CpG, and poly(I:C) were injected into established
B16F10 tumors every other day X 5 (Fig. 3). All injections
containing one or more of the three immunostimulants inhibited
tumor growth (Figs. 3A, 3B, and 3C, p,0.01 from day 12 by
Student’s t test compared with pcDNA3.1). Importantly, the triple
combination of pSP-D-CD40L + CpG + poly(I:C) was signifi-
cantly better at slowing tumor growth when compared to the
double combination of CpG + poly(I:C) without pSP-D-CD40L
(substituting pcDNA3.1 instead, Fig. 3C, p,0.05 from day 24 by
Student’s t test). Similarly, a significant survival advantage was
seen with all compound combinations compared to pcDNA3.1
empty plasmid vector (Fig. 3D, 3E, and 3F, p,0.01 by log-rank
test). Additionally, the triple combination showed a trend to
improved survival beyond that induced by any two combinations
of pSP-D-CD40L, CpG or poly(I:C), although this did not reach
statistical significance in the small number of animals used in this
study (Fig. 3F, n=5/group). Interestingly, in the mice cured of
B16F10 melanoma in 11 experiments, there was no autoimmune
loss of pigmentation (vitiligo) even after four months of
observation.
Mice cured of tumors were resistant to rechallenge with
the same tumor type
There are many possible antitumor mechanisms that could
account for the effects shown in the previous experiments. To
determine if immunological memory was generated during tumor
eradication, mice cured of B16F10 for greater than 90 days were
resistant to rechallenge with the homologous tumor cell line (data
not shown). In a related study of AB1 mesothelioma treatment
with pSP-D-CD40L and TLR agonists, the cured mice were
resistant to homologous AB1 rechallenge but not to a heterologous
A20 tumor challenge [57]. Taken together, these data indicate
that a specific memory response was present after tumor cure and
argue against a long lasting non-specific increase in non-immune
antitumor mechanisms.
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Given the promising data of Fig. 2, further studies were done to determine the relative contributions of pSP-D-CD40L, CpG, and poly(I:C) and the
effects of using them in a triple combination. Twelve groups of mice (5/group) were studied in parallel. For display purposes, the data are grouped
into three rows of graphs focusing on CpG (top row), poly(I:C) (middle row), and CpG + poly(I:C) (bottom row). Panels A, B, and C – While each
individual agent slowed tumor growth, the most significant antitumor effect was produced by the combination of pSP-D-CD40L +
CpG + poly(I:C). Panel A shows that CpG alone significantly slowed tumor growth compared to either PBS or pcDNA3.1 alone from day 12 (p,0.01
by Student’s t test, mean6SEM, n=5). In this fully controlled experiment, however, it was clear that the addition of pSP-D-CD40L to CpG produced no
further antitumor effects (p.0.05). Similarly, Panel B shows that poly(I:C) alone significantly slowed tumor growth when compared to PBS or
pcDNA3.1 alone from day 12 (p,0.01). Again, however, the combination of pSP-D-CD40L + poly(I:C) produced no further antitumor effects (p.0.05).
Interestingly, as shown in Panel C, the double combination of CpG + poly(I:C) significantly reduced tumor growth beyond that produced by CpG
alone (p,0.05 on day 24 on the combination as compared to CpG alone). The addition of pSP-D-CD40L to the two TLR agonists, CpG and poly(I:C),
produced an even stronger antitumor effect (Panel C, p,0.05 on day 24 comparing the triple combination to CpG + poly(I:C)). Panels D, E, and F –
For survival, the addition of pSP-D-CD40L did not increase the antitumor effects seen with CpG alone. All three agents (pSP-D-CD40L,
CpG, and poly(I:C)) improved survival as single therapies. From pairwise comparisons, the survival benefit was greatest with CpG and less prominent
with pSP-D-CD40L and poly(I:C). The combination of CpG + poly(I:C) improved survival further compared to poly(I:C) alone (p,0.05 by log-rank test).
Although the effects on tumor growth indicated that the double combination of TLR agonists CpG + poly(I:C) was better than each alone, this was
not reflected in the survival data. Similarly, the superiority of the triple combination of pSP-D-CD40L + CpG + poly(I:C) seen in the tumor growth
studies was not statistically significant from the survival data.
doi:10.1371/journal.pone.0007334.g003
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immunotherapy
Given the possible role of adaptive immunity in tumor
eradication, tumor sections were analyzed for the presence or
absence of immune cells, including DCs, CD8+ T cells, and
macrophages. B16F10 tumors were treated with pSP-D-CD40L +
CpG + poly(I:C) five times as detailed in Materials and Methods,
followed by tumor dissection two days later. At this time point, the
tumors treated with pSP-D-CD40L + CpG + poly(I:C) had an
increased number of necrotic areas compared to PBS treated
tumors, as shown by hematoxylin and eosin staining (Fig. 4A).
These cells were identified as necrotic because there was no
significant increase in apoptosis compared to baseline as detected
by TUNEL staining (data not shown).
To identify immune cells within the tumors, frozen sections
were stained for the presence of CD11c+ DCs, CD8+ T cells, and
F4/80+ macrophages (Figs. 4B–4D). Tumors treated with pSP-D-
CD40L + CpG + poly(I:C) showed a decrease in intratumoral
dendritic cells (Fig. 4B). This may have resulted from the
activation of these cells followed by their migration to the
tumor-draining lymph nodes (TDLNs) [58]. Consistent with this
interpretation, there was an influx of CD8+ T cells (Fig. 4C),
suggesting a role for CD8+ T cell mediated activity in the anti-
tumor activity observed. In a related study of AB1 mesothelioma, a
dense tumor for which pSP-D-CD40L injections were not very
effective, we observed a large macrophage infiltration [57]. CD40-
activated macrophages could potentially mediate tumor cell death
by expressing TRAIL, although no evidence for TRAIL was found
in a study of B16 melanoma treated with agonistic anti-CD40
antibody plus CpG [59]. However, very little macrophage influx
was seen in the present study of B16F10 tumors (Fig. 4D),
suggesting fine differences in the mode of tumor eradication that
could be related to differences in the microenvironment of these
different tumor types.
Enhanced pSP-D-CD40L DNA delivery using
polyethylenimine (PEI) or C32 nanoparticles combined
with CpG and poly(I:C) led to very strong antitumor
effects and long-term tumor-free survival
As previously shown by Anderson et al., intratumoral injection
of ‘‘naked’’ DNA is a very inefficient way to express a plasmid
transgene in tumors. However, intratumoral injection of nano-
particles formed from plasmid DNA and cationic polymers such as
PEI is dramatically better at producing transgene expression. C32,
a novel poly(beta-amino esters) cationic polymer, is even more
effective than PEI for intratumoral injection [34]. Consequently,
these DNA delivery agents were studied in the B16F10 tumor
model.
In Vivo JetPEI
TM is a commercial preparation of polyethyle-
nimine that has been optimized for in vivo transfection [60]. In
Fig. 5, nanoparticles formed using JetPEI
TM and plasmid DNA
were compared with injections of plasmid DNA alone. As before,
intratumoral injections of pSP-D-CD40L alone slowed tumor
growth (Fig. 5A) and prolonged survival (Fig. 5B), and the
antitumor effect was markedly augmented by combination with
CpG and especially CpG + poly(I:C). Remarkably, however, pSP-
Figure 4. Tumor-dependent differences in the immunohistology of induced tumor regression. Panel A – Histology of control and
treated tumors. Tumors were injected every other day X 5 with PBS as a control or with the triple combination of pSP-D-CD40L + CpG + poly(I:C). As
shown in Figure 3, the triple combination slowed the growth of tumors, and occasionally led to tumor eradication. Two days after the last injection,
tumor tissue was processed for histology by staining with hematoxylin and eosin. Tumors treated with PBS showed areas of spontaneous necrosis
suggesting that the rapidly growing tumor cells often outgrow their blood supply. After treatment with the triple combination, large areas of necrotic
tissue appeared containing fragmented cells and nuclear remnants consistent with a cell death process that exceeded the availability of phagocytic
macrophages to clear the debris (see Panel D). Panel B – CD11c antibody staining for dendritic cells. B16F10 tumors injected with PBS as a
control contained identifiable CD11c+ dendritic cells. After treatment with the triple combination, even fewer dendritic cells were found in the
tumors. Panel C – CD8 antibody staining. For tumors injected with PBS as a control, relatively few CD8+ T cells were seen. However, following
injections with the triple combination, there was a marked increase in intratumoral CD8+ T cells in all tumor sections examined. Panel D – F4/80
antibody staining for macrophages. Tumors injected with PBS as a control contained relatively few F4/80+ macrophages and there was no
appreciable increase in F4/80+ macrophages following treatment with the triple combination.
doi:10.1371/journal.pone.0007334.g004
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improved antitumor activity. PEI pSP-D-CD40L nanoparticles
controlled tumor growth nearly as well as the triple combination of
pSP-D-CD40L naked DNA plus CpG and poly(I:C). Even more
striking, PEI pSP-D-CD40L nanoparticles combined with CpG +
poly(I:C) strongly reduced B16F10 tumor growth and lead to long-
term, tumor-free survival of ,40% of mice in repeated
experiments. These cured mice remained tumor-free for over a
year, did not have vitiligo or other signs of autoimmunity, and
resisted re-challenge with B16F10 melanoma.
While these results with PEI pSP-D-CD40L nanoparticles were
exciting, other experiments indicated that PEI nanoparticles made
with pcDNA3.1 control plasmid DNA also had low-level
antitumor activity. Furthermore, scarring was observed at the site
of PEI nanoparticle injection, confirming the cytotoxicity of PEI
previously reported by others [61]. Given these limitations, we also
tested C32, a novel poly(beta-amino esters) polymer that was
selected from a polymer library based on its superior in vitro
transfection activity. More importantly, as shown by Anderson et
al., gene expression form intratumoral injections of C32 plasmid
DNA nanoparticles was 4-fold stronger than with PEI nanopar-
ticles and 26-fold stronger than intratumoral injection with naked
DNA. Also, unlike PEI, C32 is nontoxic to cells in vitro [34].
As shown in Fig. 6, C32 nanoparticles also enhanced the
antitumor effects of pSP-D-CD40L when combined with CpG +
poly(I:C). In this case, C32 pSP-D-CD40L nanoparticles were not
significantly better than that of pSP-D-CD40L naked DNA either
in terms of tumor growth (Fig. 6A) or survival (Fig. 6B), a
reproducible finding in three experiments. However, combining
C32 pcDNA3.1 nanoparticles with CpG + poly(I:C) led to very
significant antitumor effects. Indeed, C32 pcDNA3.1 nanoparti-
cles combined with CpG + poly(I:C) was nearly as effective as pSP-
D-CD40L naked DNA combined with CpG + poly(I:C) both in
terms of tumor growth (Fig. 6A) and prolongation of survival
(Fig. 6B). However, consistently superior antitumor activity was
found using C32 pSP-D-CD40L nanoparticles combined with
Figure 5. PEI nanoparticle delivery of pSP-D-CD40L slowed tumor growth and prolonged survival. The data shown are representative of
three independent experiments. Panel A – Antitumor effects of PEI plasmid DNA nanoparticles prepared with pSP-D-CD40L alone or in
combination with CpG or CpG + poly(I:C). The role of DNA transfection efficiency was tested by preparing nanoparticles formed from PEI and
pSP-D-CD40L plasmid DNA. Intratumoral injections of PEI pSP-D-CD40L nanoparticles led to significantly slower tumor growth (p,0.05 on day 10)
when compared to the injection of naked pSP-D-CD40L plasmid alone. Panel B – Survival benefit of PEI pSP-D-CD40L nanoparticle
injections in combination with CpG + poly(I:C). As expected from the tumor growth data, pSP-D-CD40L formulated with PEI was able to
enhance mouse survival when combined with CpG and poly(I:C) TLR agonists. This combination therapy resulted in long-term-tumor free survival of
2/5 mice (p,0.01 compared to pcDNA3.1)).
doi:10.1371/journal.pone.0007334.g005
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D-CD40L when combined with CpG + poly(I:C). From these
data, we conclude that the C32 nanoparticle system may have an
important role in advanced tumor immunotherapies based on
pSP-D-CD40L in combination with TLR agonists.
Discussion
These studies were undertaken to test the hypothesis that
immune activators could induce significant antitumor effects in
immunocompetent mice without using added tumor antigens.
Two categories of agents were selected for study: CD40L and
TLR agonists. Numerous studies have shown that strong CD40
stimulation can lead to the eradication of established tumors
[8,9,10,12,20,62]. Particularly noteworthy was the demonstration
by van Mierlo et al. that agonistic anti-CD40 antibody leads to the
rejection of tumors formed by malignant cells that themselves lack
the CD40 receptor, indicating that a primary effect of this
treatment is on the host immune response and not necessarily on
the tumor cells themselves [12]. Expanding upon this concept,
Hanks et al. constructed transgenic mice with DCs expressing a
CD11c promoter-driven CD40 intracytoplasmic construct that
could be multimerized by the addition of a cell-permeable
chemical crosslinker. In the TRAMP-C model of spontaneous
prostate tumor formation, the simple addition of the chemical
crosslinker that only activated CD40 downstream pathways in
dendritic cells was sufficient to lead to tumor eradication [62]. One
potential mechanism of CD40 antitumor activity is through Th17
cells. CD40 stimulation has been shown to generate IL-23 and IL-
6 which promote the activity of Th17 cells and can lead to anti-
B16-F10 activity [63,64]. Also, when CD8+ T cells are elicited by
CD40-stimulated DCs, these cells do not express the negatively
acting PD-1 surface protein, in contrast to other methods of DC
activation [65]. These studies underscore the potential significance
of CD40 stimulation as the foundation of an antitumor
immunotherapy, and also prove the requirement for CD40
multimerization to provide optimal DC activation.
A number of studies have shown that many effects of CD40
stimulation are significantly magnified by an additional TLR
stimulus. For example, CD40 stimulation alone induced DCs to
produce only modest levels of IL-12p70, whereas the addition of
Figure 6. C32 nanoparticle delivery of pSP-D-CD40L slowed tumor growth and prolonged survival. The data shown are representative
of three independent experiments. Panel A – Antitumor effects of C32 nanoparticles prepared with pSP-D-CD40L plasmid vs. control
pcDNA3.1 plasmid either alone or in combination with CpG or CpG + poly(I:C). The role of DNA transfection efficiency was tested by
preparing nanoparticles formed from C32 and pSP-D-CD40L or C32 and control pcDNA3.1 plasmid DNA. Intratumoral injections of C32 pSP-D-CD40L
nanoparticles plus CpG + poly(I:C) led to significantly slower tumor growth when compared to the injection of naked pSP-D-CD40L plasmid + CpG +
poly(I:C) (p,0.01 on day 24). Panel B – Survival benefits of C32 pSP-D-CD40L nanoparticle injections in combination with CpG +
poly(I:C). As expected from the tumor growth data, injections of nanoparticles formulated with C32 and pSP-D-CD40L enhanced survival when
combined with CpG + poly(I:C) TLR agonists. Although this survival benefit was not significantly better than a similar combination using pcDNA3.1
nanoparticles instead of pSP-D-CD40L nanoparticles (p.0.05), it was significantly better than pSP-D-CD40L naked DNA plus CpG + poly(I:C) (p,0.01).
doi:10.1371/journal.pone.0007334.g006
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IL-12p70 production [26,53,66]. Consistent with this CD40/TLR
synergy in vitro, Ahonen et al. showed that CD40 stimulation
combined with various TLR agonists could be used to generate
exceptionally strong CD8 responses in vaccinated mice [13]. Their
more recent studies showed that tumor antigen plus agonistic anti-
CD40 antibody combined with a TLR7 agonist reduced B16F10
lung metastases in mice, though the treatment began only four
days after the intravenous injection of tumor cells, rather than
being tested on established tumors [67]. To understand the
mechanism of combined therapy, Zhu et al. established a role for
MyD88-dependent and independent pathways in the interplay
between different TLR agonists [68], a hypothesis that could also
be applied to MyD88-independent, CD40-mediated stimulation.
Taken together, these studies provided the rationale for combining
CD40L with TLR agonists in the present study.
A principal result was that pSP-D-CD40L has antitumor
activity when injected directly into the tumor bed. This route of
injection was modeled after numerous studies showing that
peritumoral injections of radioactive tracers quickly localize to
the tumor draining lymph nodes (TDLNs), a technique that is in
wide use for ‘‘sentinel node biopsies’’ in breast cancer surgery.
There is a great deal of evidence that TDLNs contain dendritic
cells already charged with tumor antigens [14,69,70,71,72]. In this
case, the protein expressed from pSP-D-CD40L injected into the
tumor bed would either be carried by lymphatics to the TDLNs,
or the plasmid DNA itself could travel to the TDLNs for uptake
and expression by DCs there. In either case, this is a very
inefficient way to introduce CD40L into a host. Studies by
Anderson et al. using a luciferase plasmid have shown that direct
intratumoral injections of naked DNA led to very little gene
expression but that this could be greatly augmented by
nanoparticle-mediated DNA delivery [34]. Consequently, the
demonstration here that pSP-D-CD40L as naked DNA slowed the
growth of B16F10 melanoma likely underestimates the true
potential of this molecule. As shown by the studies with PEI
(Fig. 5) and C32 (Fig. 6) nanoparticles, improved methods of DNA
delivery are essential to define the full potential of pSP-D-CD40L
for tumor immunotherapy.
Given this caveat, it is remarkable that CD40L/TLR agonist
synergies were detected. For B16F10 melanoma, the antitumor
effect of combined CpG + poly(I:C) was enhanced by the addition
of pSP-D-CD40L naked DNA (Fig. 3A). Another result of this
study was the effectiveness of TLR agonists as antitumor agents, as
previously described in other reports. In an initial screen for
synergy with pSP-D-CD40L, several agents showed no demon-
strable effects (Pam3CSK4, Malp2, FSL1, MPL, imiquimod).
These are hydrophobic compounds whose formulation may not
have been optimal for this mode of delivery. Nevertheless, this
schedule of repeated administration of TLR agonists is in line with
the results of Yang et al. who found that TLR agonists could
induce antitumor effects but only if they were repeatedly
administered [5]. However, the limitation to 5 treatments over
an 8 day period described in the present study was somewhat
arbitrary, and the effects of a longer treatment protocol remain to
be examined.
CpG emerged as an impressive antitumor TLR agonist in these
studies, as previously described. Vicari et al. combined intratu-
moral CpG injections with systemic anti-IL10R antibody leading
to the eradication of established B16F10 melanoma [4], an effect
that depended upon endogenous CD40L [73]. Also, the combined
administration of CpG and poly(I:C) synergistically elicited strong
IL-12 production and antitumor activity against lung metastases
[74]. However, there is a species difference for the expression of
TLR9, the receptor for CpG, which is present on both myeloid
and plasmacytoid DCs in the mouse but is restricted to
plasmacytoid DCs in humans [75]. As a result of this difference,
it has been argued that conclusions drawn from murine studies of
CpG might be difficult to translate to human clinical trials. It is
reassuring, therefore, that at least two pathways in humans have
been shown to lead from CpG-initiated immunostimulation of
TLR9+ plasmacytoid DCs to the activation of TLR9- myeloid
DCs. Gerosa et al. found that CpG-activated human plasmacytoid
DCs activated NK cells which in turn matured myeloid DCs for
antigen presentation and for IL-12p70 production through a
pathway that was at least partially dependent on NK cell-myeloid
DC cell-cell contact [76]. Similarly, Gautier et al. found that type I
interferon production from CpG-stimulated human plasmacytoid
DCs could enhance IL-12p70 production by myeloid DCs [77].
The activity of poly(I:C) as an antitumor agent replicates many
previous studies performed over the past 40 years [78]. While
poly(I:C) is usually considered to be a dsRNA stimulator of TLR3
that leads to Type I interferon production, it is also an activator of
MDA5, a helicase containing a CARD motif that can lead to IL-
1beta processing and secretion [79]. The exact pathway by which
poly(I:C) is acting in the present system remains to be established.
The histological studies that were performed are consistent with
current concepts on how an intratumoral treatment might lead to
tumor rejection. The apparent decrease in intratumoral CD11c+
DCs following treatment (Fig. 4B) is consistent with DC activation,
a shift to CCR7 expression, and chemotaxis through lymphatics to
the TDLNs [58]. Giuducci et al demonstrated such DC
movements using FITC-labeled beads as a tracer within 6 hours
of initiating immunotherapy with intratumoral AdCCL16 and
systemic CpG and anti-IL-10R antibody in TSA breast tumors in
mice [73]. The appearance of CD8+ T cells in the tumors is
consistent with the recognized antitumor effects of these cytotoxic
cells (Fig. 4C).
Finally, nanoparticles formed from plasmid DNA and cationic
polymers such as PEI or C32 can play a crucial role in augmenting
the effectiveness of certain immunostimulatory combinations.
While both polymers augment plasmid-directed gene expression
after intratumoral injection, C32 was shown to be significantly
stronger than PEI, and also C32 lacks the cytotoxicity caused by
PEI [34]. Using either PEI or C32, pSP-D-CD40L-containing
nanoparticles were superior to control pcDNA3.1-containing
nanoparticles when used in combination with CpG + poly(I:C)
(Figs. 5 and 6).
However, there are fine differences between PEI and C32. PEI
enhances the antitumor activity of pSP-D-CD40L by itself
(compare pSP-D-CD40L naked DNA with PEI pSP-D-CD40L
nanoparticles in Fig. 5). In contrast, C32 does not increase the
antitumor activity of pSP-D-CD40L by itself (compare pSP-D-
CD40L naked DNA with C32 pSP-D-CD40L nanoparticles in
Fig. 6). There are two possible explanations for this difference.
First, neither polymer is immunologically neutral. PEI was recently
reported to be a strong TLR5 agonist that activates cells through a
MyD88-dependent pathway [80], much like flagellin which is the
prototypic TLR5 agonist. Likewise, C32 was shown to be an
adjuvant for CD8+ T cell responses following intramuscular DNA
vaccination using complexes of C32 and a plasmid for HIV gp120.
In that case, C32 was used at a 2:1 ratio of polymer to DNA rather
than the 20:1 ratio used in the present study [81]. Second, both
cationic polymers are designed to help the plasmid DNA escape
degradation in the lysosome and thereby favor the release of DNA
into the cytoplasm. Such lysosomal damage could lead to
activation of the NALP3 inflammasome pathway and result in
the production of immunostimulants including IL-1b and IL-6 by
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nanoparticles differ in their ability to activate the inflammasome
pathway following intratumoral injection. As a further complexity,
CD40L has been shown to downregulate NALP3-mediated
inflammasome activation in macrophages, thereby suppressing
the inflammasome-triggered release of inflammatory cytokines
[83]. Perhaps this CD40-mediated inflammasome suppression is
offset by the strong stimulation provided by CpG + poly(I:C) in a
way that maintains the release of IL-1b and IL-6. Such complex
interactions could underlie the need for combinations of
immunostimulants to produce the strong antitumor effects
observed in these experiments.
Antitumor immune responses are frequently associated with
autoimmunity. In the case of B16F10 melanoma, autoimmunity
takes the form of loss of pigment (vitiligo) caused by immune
damage to normal melanocytes [31]. Although the combination
therapy described here had significant antitumor effects on
B16F10 melanoma, vitiligo was not seen. This is only the fifth
report of a method to induce significant anti-melanoma immune
responses without eliciting autoimmune vitiligo [84,85,86,87]. The
only toxic effect noted was a transient 2–3 fold increase in spleen
size in the CpG treated mice consistent with previous reports that
CpG induces extramedullary hematopoiesis in this organ [88].
In conclusion, the B16F10 melanoma model is an extremely
difficult tumor to treat using immunotherapy approaches [89],
which makes it an excellent system to identify immunotherapy
formulations strong enough to translate into a clinical benefit for
humans. Using this system, intratumoral injections of plasmid
DNA encoding multimeric soluble CD40L (pSP-D-CD40L)
demonstrated antitumor activity under certain circumstances
and were especially effective when combined with TLR3 and
TLR9 agonists. Many other TNF superfamily molecules have
been found to have antitumor potential [90] and these could also
be tested against B16F10 tumors using an adaptation of these
methods (as an example, note the antitumor effects shown for pSP-
D-GITRL in Fig. 1). The combination immunotherapy protocol
described herein was non-toxic and did not elicit autoimmune
effects such as vitiligo. A transient increase in spleen size related to
CpG was the only negative effect detected. These results show the
potential of immunostimulatory combinations for antitumor
therapy and encourage further experiments to delineate the
optimal use and role of each component in pSP-D-CD40L
nanoparticle plus CpG and poly(I:C) approach.
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